LOGIN  |  REGISTER
Recursion
Viking Therapeutics

LeMaitre Vascular to Participate at Upcoming Investor Conferences in September

August 27, 2024 | Last Trade: US$94.48 0.54 -0.57

BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September.

Morgan Stanley 22nd Annual Global Healthcare Conference
Wednesday, September 4, 2024
New York Marriott Marquis, New York, NY
David Roberts, President, will present at 5:35 PM EST

Barrington Research Fall Investment Conference (Virtual)
Thursday, September 12, 2024
George W. LeMaitre, Chairman & CEO, is scheduled to host a series of 1x1 meetings

Cantor Fitzgerald 2024 Global Healthcare Conference
Thursday, September 19, 2024
InterContinental New York Barclay Hotel, New York, NY
David Roberts, President, will present at 8:00 AM EST

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page